CannBioRx Life Sciences Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.008
- Today's High:
- $0.0115
- Open Price:
- $0.0115
- 52W Low:
- $0.0106
- 52W High:
- $0.3529
- Prev. Close:
- $0.0101
- Volume:
- 17196
Company Statistics
- Market Cap.:
- $250.78 million
- Book Value:
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -42.24%
- Return on Equity TTM:
- -3754.4%
Company Profile
CannBioRx Life Sciences Corp had its IPO on 2017-06-27 under the ticker symbol ATNFW.
The company operates in the sector and industry. CannBioRx Life Sciences Corp has a staff strength of 0 employees.
Stock update
Shares of CannBioRx Life Sciences Corp opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.01, and closed at $0.01.
This is a +2.97% increase from the previous day's closing price.
A total volume of 17,196 shares were traded at the close of the day’s session.
In the last one week, shares of CannBioRx Life Sciences Corp have increased by +4%.
CannBioRx Life Sciences Corp's Key Ratios
CannBioRx Life Sciences Corp has a market cap of $250.78 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months CannBioRx Life Sciences Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-20990946. The EBITDA ratio measures CannBioRx Life Sciences Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CannBioRx Life Sciences Corp’s operating margin was 0% while its return on assets stood at -42.24% with a return of equity of -3754.4%.
In Q1, CannBioRx Life Sciences Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
CannBioRx Life Sciences Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CannBioRx Life Sciences Corp’s profitability.
CannBioRx Life Sciences Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
CannBioRx Life Sciences Corp stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $14.92 million
- Total Liabilities
- $5.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
CannBioRx Life Sciences Corp ended 2024 with $14.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.92 million while shareholder equity stood at $7.14 million.
CannBioRx Life Sciences Corp ended 2024 with $2.63 million in deferred long-term liabilities, $5.12 million in other current liabilities, 375.00 in common stock, $-112170623.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.65 million and cash and short-term investments were $2.65 million. The company’s total short-term debt was $842,202 while long-term debt stood at $28732.00.
CannBioRx Life Sciences Corp’s total current assets stands at $4.20 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $357497.00 compared to accounts payable of $1.21 million and inventory worth $0.
In 2024, CannBioRx Life Sciences Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, CannBioRx Life Sciences Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $0.3529
- 52-Week Low
- $0.0106
- Analyst Target Price
- $
CannBioRx Life Sciences Corp stock is currently trading at $0.01 per share. It touched a 52-week high of $0.3529 and a 52-week low of $0.3529. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.01 and 200-day moving average was $0.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About CannBioRx Life Sciences Corp
Most Active
Top Gainers
Top Losers
About
180 Life Sciences Corp., a clinical-stage biotechnology company, focuses on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis, and pain. Its primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial. The company is headquatered in Menlo Park, California.